Merck shows dedication in 40 conference presentations
The presentations include data from several of the company’s established and investigational infectious disease products.
“Merck is one of a few large pharmaceutical companies that have remained deeply committed to developing novel anti-infective therapies,” Dr. Julie Gerberding, executive vice president, strategic communications, global public policy and population health, Merck, said. “Today, with increasing concerns about the rise of antimicrobial resistance, we continue to advocate for appropriate and responsible use of these important medicines.”
The presentations will be given between Sept. 17 and 21 at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) meeting that will be held in San Diego, California.
“At Merck we continue to advance a broad portfolio of investigational infectious disease medicines,” Dr. Eliav Barr, vice president of infectious diseases, Merck Research Laboratories, said. “We look forward to presenting data at ICAAC/ICC with a focus on our antibacterial candidates designed to address serious infections such as C. difficile and the increasing threats presented by resistant Gram-negative bacteria.”